Islam M. Miligy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Islam M. Miligy has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Michael S. Toss
16 shared publicationsAbdulbaqi Al-Kawaz
13 shared publications- Claire Seedhouse
Translational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom
13 shared publications - Katia A. Mesquita
Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 3RD, UK
13 shared publications Reem Ali
13 shared publicationsSameer Mirza
13 shared publications
Latest Publications
- Open Access
- 5 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7381
Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers
Oestrogen receptor (ER)-positive breast cancer (BC) is generally well responsive to endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for downstaging ER-positive tumours. This study aims to analyse the effect of NAET on a well-characterised cohort of ER-positive BC with particular emphasis on receptor expression. This is a retrospective United Kingdom (UK) multicentre study of 391 patients who received NAET between October 2012 and October 2020. Detailed analyses of the paired pre- and post-NAET morphological changes and hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression were performed. The median duration of NAET was 86 days, with median survival and overall survival rates of 380 days and 93.4%, respectively. A total of 90.3% of cases achieved a pathological partial response, with a significantly higher rate of response in the HER2-low cancers. Following NAET, BC displayed some pathological changes involving the tumour stroma including central scarring and an increase in tumour infiltrating lymphocytes (TILs) and tumour cell morphology. Significant changes associated with the duration of NAET were observed in tumour grade (30.6% of cases), with downgrading identified in 19.3% of tumours (p < 0.001). The conversion of ER status from positive to low or negative was insignificant. The conversion of progesterone receptor (PR) and HER2 status to negative status was observed in 31.3% and 38.1% of cases, respectively (p < 0.001). HER2-low breast cancer decreased from 63% to 37% following NAET in the paired samples. Significant morphological and biomarker changes involving PR and HER2 expression occurred following NAET. The findings support biomarker testing on pre-treatment core biopsies and post-treatment residual carcinoma.
- 5 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7381
Open AccessPathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers
Oestrogen receptor (ER)-positive breast cancer (BC) is generally well responsive to endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for downstaging ER-positive tumours. This study aims to analyse the effect of NAET on a well-characterised cohort of ER-positive BC with particular emphasis on receptor expression. This is a retrospective United Kingdom (UK) multicentre study of 391 patients who received NAET between October 2012 and October 2020. Detailed analyses of the paired pre- and post-NAET morphological changes and hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression were performed. The median duration of NAET was 86 days, with median survival and overall survival rates of 380 days and 93.4%, respectively. A total of 90.3% of cases achieved a pathological partial response, with a significantly higher rate of response in the HER2-low cancers. Following NAET, BC displayed some pathological changes involving the tumour stroma including central scarring and an increase in tumour infiltrating lymphocytes (TILs) and tumour cell morphology. Significant changes associated with the duration of NAET were observed in tumour grade (30.6% of cases), with downgrading identified in 19.3% of tumours (p < 0.001). The conversion of ER status from positive to low or negative was insignificant. The conversion of progesterone receptor (PR) and HER2 status to negative status was observed in 31.3% and 38.1% of cases, respectively (p < 0.001). HER2-low breast cancer decreased from 63% to 37% following NAET in the paired samples. Significant morphological and biomarker changes involving PR and HER2 expression occurred following NAET. The findings support biomarker testing on pre-treatment core biopsies and post-treatment residual carcinoma.
- Open Access
- 7 June 2024
- Published by Wiley in Histopathology
- Vol. 85 (3) , 405-417
Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study
Aims: Standard neoadjuvant endocrine therapy (NAET) is used for 6–9 months to downstage hormone‐receptor‐positive breast cancer. Bridging ET was introduced during the COVID‐19 pandemic to delay surgical intervention. There are no data in the literature on the effect of short course therapy on tumour response. We aimed to analyse the effect of bridging ET and validate the previously proposed neoadjuvant ET pathological reporting criteria.Methods and Results: This was a multicentre cohort of 256 patients who received bridging ET between March and October 2020. Assessment of paired pre‐ and post‐NAET hormone receptors and HER2 and posttherapy Ki67 expression was done. The median duration of NAET was 45 days. In all, 86% of cases achieved partial pathological response and 9% showed minimal residual disease. Histological response to ET was observed from as early as day 6 posttherapy. Central scarring was noted in 32.8% of cases and lymphocytic infiltrate was seen in 43.4% of cases. Significant changes associated with the duration of ET were observed in tumour grade (21%), with downgrading identified in 12% of tumours (P < 0.001), progesterone receptor (PR) expression with switch to PR‐negative status in 26% of cases (P < 0.001), and HER2 status with a switch from HER2‐low to HER2‐negative status in 32% of cases (P < 0.001). The median patient survival was 475 days, with an overall survival rate of 99.6%.Conclusions: Changes characteristic of tumour regression and significant changes in PR and HER2 occurred following a short course of NAET. The findings support biomarker testing on pretreatment core biopsies and retesting following therapy.
- 7 June 2024
- Published by Wiley in Histopathology
- Vol. 85 (3) , 405-417
Open AccessMorphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study
Aims: Standard neoadjuvant endocrine therapy (NAET) is used for 6–9 months to downstage hormone‐receptor‐positive breast cancer. Bridging ET was introduced during the COVID‐19 pandemic to delay surgical intervention. There are no data in the literature on the effect of short course therapy on tumour response. We aimed to analyse the effect of bridging ET and validate the previously proposed neoadjuvant ET pathological reporting criteria.Methods and Results: This was a multicentre cohort of 256 patients who received bridging ET between March and October 2020. Assessment of paired pre‐ and post‐NAET hormone receptors and HER2 and posttherapy Ki67 expression was done. The median duration of NAET was 45 days. In all, 86% of cases achieved partial pathological response and 9% showed minimal residual disease. Histological response to ET was observed from as early as day 6 posttherapy. Central scarring was noted in 32.8% of cases and lymphocytic infiltrate was seen in 43.4% of cases. Significant changes associated with the duration of ET were observed in tumour grade (21%), with downgrading identified in 12% of tumours (P < 0.001), progesterone receptor (PR) expression with switch to PR‐negative status in 26% of cases (P < 0.001), and HER2 status with a switch from HER2‐low to HER2‐negative status in 32% of cases (P < 0.001). The median patient survival was 475 days, with an overall survival rate of 99.6%.Conclusions: Changes characteristic of tumour regression and significant changes in PR and HER2 occurred following a short course of NAET. The findings support biomarker testing on pretreatment core biopsies and retesting following therapy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Targeting PARP1 for synthetic lethality is a new strategy for breast cancers harboring germline mutations in BRCA. However, these mutations are rare, and reactivation of BRCA-mediated pathways may result in eventual resistance to PARP1 inhibitor therapy. Alternative synthetic lethality approaches targeting more common sporadic breast cancers and preinvasive ductal carcinoma in situ (DCIS) are desirable. Here we show that downregulation of XRCC1, which interacts with PARP1 and coordinates base excision repair, is an early event in human breast cancer pathogenesis. XRCC1-deficient DCIS were aggressive and associated with increased risk of local recurrence. Human invasive breast cancers deficient in XRCC1 and expressing high PARP1 levels also manifested aggressive features and poor outcome. The PARP1 inhibitor olaparib was synthetically lethal in XRCC1-deficient DCIS and invasive breast cancer cells. We conclude that targeting PARP1 is an attractive strategy for synthetic lethality and chemoprevention in XRCC1-deficient breast cancers, including preinvasive DCIS.Significance:These findings show that loss of XRCC1, which is associated with more malignant DCIS, can be exploited by PARP inhibition, suggesting its application as a promising therapeutic and chemoprevention strategy in XRCC1-deficient tumor cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Targeting PARP1 for synthetic lethality is a new strategy for breast cancers harboring germline mutations in BRCA. However, these mutations are rare, and reactivation of BRCA-mediated pathways may result in eventual resistance to PARP1 inhibitor therapy. Alternative synthetic lethality approaches targeting more common sporadic breast cancers and preinvasive ductal carcinoma in situ (DCIS) are desirable. Here we show that downregulation of XRCC1, which interacts with PARP1 and coordinates base excision repair, is an early event in human breast cancer pathogenesis. XRCC1-deficient DCIS were aggressive and associated with increased risk of local recurrence. Human invasive breast cancers deficient in XRCC1 and expressing high PARP1 levels also manifested aggressive features and poor outcome. The PARP1 inhibitor olaparib was synthetically lethal in XRCC1-deficient DCIS and invasive breast cancer cells. We conclude that targeting PARP1 is an attractive strategy for synthetic lethality and chemoprevention in XRCC1-deficient breast cancers, including preinvasive DCIS.Significance:These findings show that loss of XRCC1, which is associated with more malignant DCIS, can be exploited by PARP inhibition, suggesting its application as a promising therapeutic and chemoprevention strategy in XRCC1-deficient tumor cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Western blots, FACS and clonogenic assays
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Western blots, FACS and clonogenic assays
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure legends from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Legends for Supplementary Figure S1 & Supplementary Figure S2
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure legends from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Legends for Supplementary Figure S1 & Supplementary Figure S2
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplemental Table S1: Clinicopathological characteristics of whole breast cancer cohort Supplemental Table S2: Clinicopathological characteristics of ER- cohort Supplementary Table S3: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker Supplementary Table S4. Clinicopathological significance of PARP and XRCC1 co-expression in breast cancers. Supplementary Table S5: Percentage of cells in various stages of cell cycle. Supplementary Table S6: Patient demographics in DCIS cohort. Supplementary Table S7: XRCC1 and clinic-pathological associations in pure DCIS cohort Supplementary Table 8: List of EMT PCR array genes layout Supplementary Table S9: LD50 for PARP inhibitor sensitivity in XRCC1 deficient/knockout cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplemental Table S1: Clinicopathological characteristics of whole breast cancer cohort Supplemental Table S2: Clinicopathological characteristics of ER- cohort Supplementary Table S3: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker Supplementary Table S4. Clinicopathological significance of PARP and XRCC1 co-expression in breast cancers. Supplementary Table S5: Percentage of cells in various stages of cell cycle. Supplementary Table S6: Patient demographics in DCIS cohort. Supplementary Table S7: XRCC1 and clinic-pathological associations in pure DCIS cohort Supplementary Table 8: List of EMT PCR array genes layout Supplementary Table S9: LD50 for PARP inhibitor sensitivity in XRCC1 deficient/knockout cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplementary materials and Methods for Compounds and reagents, Generation of XRCC1 knockouts using CRISPR/Cas-9 system, Clonogenic assays, Cell Proliferation assays, Cell synchronization and functional studies, Confocal microscopy, Invasion and migration assays, qRT-PCR analysis of epithelial-mesenchymal transition (EMT) gene expression, Generation of 3D spheroids, human Invasive breast cancers and DCIS cohorts (demographics and treatment).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplementary materials and Methods for Compounds and reagents, Generation of XRCC1 knockouts using CRISPR/Cas-9 system, Clonogenic assays, Cell Proliferation assays, Cell synchronization and functional studies, Confocal microscopy, Invasion and migration assays, qRT-PCR analysis of epithelial-mesenchymal transition (EMT) gene expression, Generation of 3D spheroids, human Invasive breast cancers and DCIS cohorts (demographics and treatment).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplementary materials and Methods for Compounds and reagents, Generation of XRCC1 knockouts using CRISPR/Cas-9 system, Clonogenic assays, Cell Proliferation assays, Cell synchronization and functional studies, Confocal microscopy, Invasion and migration assays, qRT-PCR analysis of epithelial-mesenchymal transition (EMT) gene expression, Generation of 3D spheroids, human Invasive breast cancers and DCIS cohorts (demographics and treatment).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplementary materials and Methods for Compounds and reagents, Generation of XRCC1 knockouts using CRISPR/Cas-9 system, Clonogenic assays, Cell Proliferation assays, Cell synchronization and functional studies, Confocal microscopy, Invasion and migration assays, qRT-PCR analysis of epithelial-mesenchymal transition (EMT) gene expression, Generation of 3D spheroids, human Invasive breast cancers and DCIS cohorts (demographics and treatment).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplemental Table S1: Clinicopathological characteristics of whole breast cancer cohort Supplemental Table S2: Clinicopathological characteristics of ER- cohort Supplementary Table S3: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker Supplementary Table S4. Clinicopathological significance of PARP and XRCC1 co-expression in breast cancers. Supplementary Table S5: Percentage of cells in various stages of cell cycle. Supplementary Table S6: Patient demographics in DCIS cohort. Supplementary Table S7: XRCC1 and clinic-pathological associations in pure DCIS cohort Supplementary Table 8: List of EMT PCR array genes layout Supplementary Table S9: LD50 for PARP inhibitor sensitivity in XRCC1 deficient/knockout cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention
Supplemental Table S1: Clinicopathological characteristics of whole breast cancer cohort Supplemental Table S2: Clinicopathological characteristics of ER- cohort Supplementary Table S3: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker Supplementary Table S4. Clinicopathological significance of PARP and XRCC1 co-expression in breast cancers. Supplementary Table S5: Percentage of cells in various stages of cell cycle. Supplementary Table S6: Patient demographics in DCIS cohort. Supplementary Table S7: XRCC1 and clinic-pathological associations in pure DCIS cohort Supplementary Table 8: List of EMT PCR array genes layout Supplementary Table S9: LD50 for PARP inhibitor sensitivity in XRCC1 deficient/knockout cells.